Week 35
Blue Light Advances to Clinical Trials for Cancer Treatment
PILLAR DIAGNOSTIC // WEEK 35
Confidence 90%
“With no unresolved divergences and robust concordant evidence from in vitro and in vivo studies demonstrating BL’s potent anti-tumor effects, we assign a low risk posture regarding the veracity of its efficacy claims. The absence of conflicting data indicates full alignment across pillars.”
Proposed action
Advance BL into early-phase clinical trial design to assess safety and preliminary efficacy in humans.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
BL exhibits potent anti-tumor activity both in vitro—reducing cell viability, proliferation, migration, invasion, increasing ROS production, and inducing apoptosis—and in vivo by inhibiting tumor growth, metastasis, and improving survival.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
—